IP Library › Granted Patent US 12,313,637
Granted Patent B2
US 12,313,637 · App. 17/242,780 · Granted May 27, 2025

Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein TDP-43

Inventors: Michael Sierks (Ft. McDowell, AZ); Stephanie Williams (Phoenix, AZ); Lalitha Venkataraman (Tempe, AZ)
Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
G01N33/6896C07K16/18C07K2317/622G01N2800/2814G01N2800/285
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,313,637
App. No.
17/242,780
Granted
May 27, 2025
Kind
B2
Abstract

The invention relates to antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with frontotemporal dementia (FTD), but not TDP-43 associated with amyotrophic lateral sclerosis (ALS) or TDP-43 associated with healthy human brain tissue, and antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with ALS, but not TDP-43 associated FTD or TDP-43 associated with healthy human brain tissue.

Claims (14)

1. An antibody or antigen binding fragment thereof comprising an amino acid sequence encoded by a nucleic acid, wherein the nucleic acid has at least 98% identity to SEQ ID NO:16.

2. A method of binding TDP-43 associated with ALS comprising contacting a composition that comprises TDP-43 associated with ALS with the antibody or antigen fragment thereof of claim 1 .

3. The method of claim 2 , wherein the TDP-43 associated with ALS is in a cell.

4. The method of claim 2 , wherein the TDP-43 associated with ALS is in brain tissue.

5. An imaging composition specific for TDP-43 associated with ALS comprising the antibody or antigen binding fragment thereof of claim 1 conjugated to an imaging agent.

6. The antibody or antigen binding fragment thereof of claim 1 , wherein the nucleic acid has at least 99% identity to SEQ ID NO:16.

7. The antibody or antigen binding fragment thereof of claim 1 , wherein the nucleic acid has 100% identity to SEQ ID NO:16.

8. A binding molecule that binds to TAR DNA binding protein 43 (TDP-43) associated with Amyotrophic Lateral Sclerosis (ALS) and does not bind TDP-43 from healthy human brain tissue or TDP-43 associated with Frontotemporal Dementia (FTD), wherein the binding molecule comprises an amino acid sequence encoded by a nucleic acid, wherein the nucleic acid has at least 98% identity to SEQ ID NO:16.

9. An imaging composition specific for TDP-43 associated with ALS comprising the binding molecule of claim 8 conjugated to an imaging agent.

10. A method of binding TDP-43 associated with ALS comprising contacting a composition that comprises TDP-43 associated with ALS with the binding molecule of claim 8 .

11. The method of claim 10 , wherein the TDP-43 associated with ALS is in a cell.

12. The method of claim 10 , wherein the TDP-43 associated with ALS is in brain tissue.

13. The binding molecule of claim 8 , wherein the nucleic acid sequence has at least 99% identity to SEQ ID NO:16.

14. The binding molecule of claim 8 , wherein the nucleic acid sequence has 100% identity to SEQ ID NO:16.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2021
From: SIERKS, MICHAEL; WILLIAMS, STEPHANIE; VENKATARAMAN, LALITHA
To: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
Reel/Frame 056070/0065 →
Continuity (4)
Continuation 16211006 · Dec 5, 2018
Continuation 15114356
Provisional Application 61934443 · Jan 31, 2014
Related Publication 20210373036A1 · Dec 2, 2021
References Cited (61)
US 8617549B2 · Sierks · 2013 [cited by applicant]
US 9938330B2 · Sierks · 2018 [cited by examiner]
US 10191068B2 · Sierks et al. · 2019 [cited by applicant]
US RE49625E · Sierks · 2023 [cited by examiner]
US 20080131423A1 · Mori et al. · 2008 [cited by applicant]
US 20100136573A1 · Petrucelli et al. · 2010 [cited by applicant]
US 20140011691A1 · Sierks et al. · 2014 [cited by applicant]
WO WO2008143708A2 · 2008 [cited by applicant]
WO WO2012042270A1 · 2012 [cited by applicant]
WO WO2012058334A1 · 2012 [cited by examiner]
WO WO2013061163A2 · 2013 [cited by applicant]
Kuriu et al (J Surg Oncol 94: 144-148, 2006). [cited by examiner]
Goswami et al, (Hybridoma 28: 327-331, 2009). [cited by examiner]
Mackenzie et al (Lancet Neurol 9: 995-1007, 2010). [cited by examiner]
Extended European Search Report in EP Application No. 15743293.1, dated Oct. 6, 2017, in 9 pages. [cited by applicant]
Goossens, Joery, et al. “TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies.” Acta Neuropathologica Communications 3.1 {2015):15, 8 pages. [cited by applicant]
Kurio et al (J Surg Oncol 94: 144-148, 2006). [cited by applicant]
Amador-Ortiz , et al., “TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease”, Annals of Neurology 61(5), 435-445 (2007). [cited by applicant]
Barkhordarian, H , et al., “Isolating recombinant antibodies against specific protein morphologies using atomic orce microscopy and phage display technologies”, Protein Eng Des Sel, 19(11), 497-502 (2006). [cited by applicant]
Buratti , et al., “Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease”, Frontiers in Bioscience 13(3), 867-878 (2008). [cited by applicant]
Buratti , et al., “Nuclear factor TDP-43 binds to the polymorphic TG repeats in CFTR intron 8 and causes skipping of exon 9: a functional link with disease penetrance”, American Journal of Human Genetics 74(6), 1322-132… [cited by applicant]
Dickson, “TDP-43 Immunoreactivity in Neurodegenerative Disease: Disease versus Mechanism-Specificity”, Acta Neuropathologica 115(1), 147-149 (2008). [cited by applicant]
El-Agnaf, 0, et al., “Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential piomarker for Parkinson's disease”, Faseb J 20, 419-425 (2006). [cited by applicant]
Emadi, S. , et al., “Detecting morphologically distinct oligomeric forms of alpha-synuclein”, J. Biol. Chem. 284 (17), 11048-11058 (2009). [cited by applicant]
Emadi, S. , et al., “Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments”, Biochemistry, vol. 43 (10), 2871-2878 (2004). [cited by applicant]
Emadi, S, et al., “Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits eggregation and prevents alpha-synuclein-induced toxicity”, J Mol Biol 368, 1132-1144 (2007). [cited by applicant]
Farmer, Jill G., et al., “Coexisting adult polyglucosan body disease with frontotemporal lobar degeneration with 10 ransactivation response DNA-binding protein-43 (TDP-43)-positive neuronal inclusions”, Neurocase 19.1 (… [cited by applicant]
Flood, D.G. , et al., “Developing predictive CSF biomarkers-A challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine”, Biochem Pharmacol. 81:p. 1422-34. [cited by applicant]
Georganopoulou , et al., “Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker or Alzheimer's disease”, PNAS USA 102(7), 2273-2276 (2005). [cited by applicant]
Geser , et al., “On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and Without dementia”, Prag Neurobiol, 95(4), 649-662, Dec. 2011. [cited by applicant]
Graber, D.J. , et al., “Progressive changes in microglia and macrophages in spinal cord and peripheral nerve in the ransgenic rat model of amyotrophic lateral sclerosis”, J Neuroinflammation 7: p. 8. [cited by applicant]
Graber, D.J. , et al., “Synthetic triterpenoid CDDO derivatives modulate cytoprotective or immunological properties in astrocytes, neurons, and microglia”, J Neuroimmune Pharmacol. 6: p. 107-20. [cited by applicant]
Herman, et al., “β-amyloid triggers ALS-associated TDP-43 pathology in AD models”, Brain Research 1386, 191-199 (2011). [cited by applicant]
Hu, et al., “Biomarkers in frontotemporal lobar degenerations—progress and challenges”, Progress in Neurobiology 95 (4), 636-648 (2011). [cited by applicant]
Hu, William T., et al., “Novel CSF biomarkers for frontotemporal lobar degenerations”, Neurology 75.23 (2010): 2079-2086. [cited by applicant]
Johnson, et al., “TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity”, Journal of Biological Chemistry 284(30), 20329-20339 (2009). [cited by applicant]
Kasturirangan , et al., “Isolation and Characterization of Antibody Fragments Selective for Specific Protein Morphologies from Nanogram Antigen Samples”, Biotechnology Progress 29(2), 463-471 (2013). [cited by applicant]
Kasturirangan, S., et al., “Nanobody specific for oligomeric [3-amyloid stabilizes nontoxic form”, Neurobiol Aging B3 (7), 1320-1328 (2012). [cited by applicant]
Liu , et al., “Proteolytic antibody light chains alter beta-amyloid aggregation and prevent cytotoxicity”, Biochemistry 43 (31), 9999-10007 (2004). [cited by applicant]
Liu, et al., “Residues 17-20 and 30-35 of beta-amyloid play critical roles in aggregation”, J Neurosci Res 75(2), 162-171 (2004). [cited by applicant]
Liu , et al., “Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity”, Biochemistry 43(22), 6959-6967 (2004). [cited by applicant]
Mackenzie, I., et al., “Nomenclature and nosology for neuropathologic subtypes offrontotemporal lobar degeneration: an update”, Acta Neuropathol, 2010. 119(1): 1-4. [cited by applicant]
Mackenzie, I, “TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia”, Lancet Neural, 9 10), 995-1007, Oct. 2010. [cited by applicant]
Marcus, et al., “Characterization of an antibody scFv that recognizes fibrillar insulin and beta-amyloid using Atomic Force Microscopy”, Nanomedicine 4(1), 1-7 (2008). [cited by applicant]
Marcus , et al., “Isolation of an scFv targeting BRG 1 using phage display with characterization by AFM”, Biochem Biophys Res Commun 342(4), 1123-1129 (2006). [cited by applicant]
Meraz-Rios, et al., “Tau oligomers and aggregation in Alzheimer's disease”, J Neurochem 112(6), 1353-1367 (2010). [cited by applicant]
Noto, et al., “Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis: specificity, sensitivity, and a possible prognostic value”, Amyotrophic Lateral Sclerosis 12(2), 140-143 (2011). [cited by applicant]
Patent Cooperation Treaty, International Searching Authority, Search Report and Written Opinion for PCT/US15/14121, 13 pages, Aug. 4, 2015. [cited by applicant]
Shl Yakhtenko, et al., “Single-molecule selection and recovery of structure-specific antibodies using atomic force microscopy”, Nanomedicine 3(3), 192-197 (2007). [cited by applicant]
Stommel, E. , et al., “Tumor necrosis factor-alpha induces changes in mitochondrial cellular distribution in motor neurons”, Neuroscience, 2007. 146(3): 1013-9. [cited by applicant]
Swarup, V. , et al., “Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in ransgenic mice produced with TDP-43 genomic fragments”, Brain 134: p. 2610-26. [cited by applicant]
Ullian, E. M., et al., “Schwann cells and astrocytes induce synapse formation by spinal motor neurons in culture”, Mal Cell Neurosci, 2004. 25: p. 241-51. [cited by applicant]
Uryu , et al., “Concomitant TAR-DNA-Binding Protein 43 Pathology Is Present in Alzheimer Disease and Corticobasa Degeneration but Not in Other Tauopathies”, Journal of Neuropathology & Experimental Neurology 67(6), 555-… [cited by applicant]
Walsh, et al., “A beta oligomers—a decade of discovery”, J Neurochem 101(5), 1172-1184 (2007). [cited by applicant]
Walsh , et al., “Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo”, Nature 416(6880), 535-539 (2002). [cited by applicant]
Wang, M., et al., “Characterizing Antibody Specificity to Different Protein Morphologies by AFM”, Langmuir, 2008. [cited by applicant]
Wilson , et al., “TDP-43 in aging and Alzheimer's disease—a review”, International Journal of Clinical & Experimental Pathology 4(2), 147-155 (2011). [cited by applicant]
Yuan , et al., “Intracellular targeting and clearance of oligomeric alpha-synuclein alleviates toxicity in mammalian cells”, Neuroscience Letters 459(1), 16-18 (2009). [cited by applicant]
Zameer, A. , et al., “Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta-induced toxicity against human neuroblastoma cells”, J Mol Biol 384 (4), 917-928 (2008). [cited by applicant]
Zameer, A , et al., “Single chain Fv antibodies against the 25-35 Abeta fragment inhibit aggregation and toxicity of Abeta42”, Biochemistry 45(38), 11532-11539 (2006). [cited by applicant]
Zhou , et al., “A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein”, Mol Ther, 10(6), 1023-1031 (2004). [cited by applicant]